Inventor · disambiguated record
Jason Yantha
Also filed as: YANTHA JASON
28 granted patents·24 pending applications·303 citations·filing 2001–2015
96Inventor score
Files withSYN X PHARMA INC14JACKOWSKI GEORGE13PIVOTAL THERAPEUTICS INC6ARTEMIS PROTEOMICS LTD3NANOGEN INC2
Top patents by PatentIndex Score
52 records- 0196US6890763B2Biopolymer marker indicative of disease state having a molecular weight of 1350 daltonsSYN X PHARMA INC·Filed 2001·Granted May 10, 2005·79 cites·6 claims
- 0284US6602855B2Biopolymer marker indicative of disease state having a molecular weight of 1449 daltonsSYN X PHARMA INC·Filed 2001·Granted Aug 5, 2003·26 cites·9 claims
- 0382US6620786B2Biopolymer marker indicative of disease state having molecular weight of 2937 daltonsSYN X PHARMA INC·Filed 2001·Granted Sep 16, 2003·19 cites·9 claims
- 0481US6627606B2Biopolymer marker indicative of disease state having a molecular weight of 1465 daltonsSYN X PHARMA INC·Filed 2001·Granted Sep 30, 2003·18 cites·9 claims
- 0581US6617308B2Biopolymer marker indicative of disease state having a molecular weight of 1865 daltonsSYN X PHARMA INC·Filed 2001·Granted Sep 9, 2003·18 cites·9 claims
- 0679US6677303B2Biopolymer marker indicative of disease state having a molecular weight of 1097 daltonsSYN X PHARMA·Filed 2001·Granted Jan 13, 2004·16 cites·9 claims
- 0779US6620787B2Biopolymer marker indicative of disease state having a molecular weight of 2267 daltonsSYN X PHARMA INC·Filed 2001·Granted Sep 16, 2003·16 cites·9 claims
- 0878US9119826B2Omega 3 fatty acid for use as a prescription medical food and omega 3 fatty acid diagniostic assay for the dietary management of cardiovascular patients with cardiovascular disease (CVD) who are deficient in blood EPA and DHA levelsJACKOWSKI GEORGE·Filed 2012·Granted Sep 1, 2015·2 cites·10 claims
- 0978US6703366B2Biopolymer marker indicative of disease state having a molecular weight of 1,896 daltonsFiled 2001·Granted Mar 9, 2004·15 cites·9 claims
- 1074US7314717B2Biopolymer marker indicative of disease state having a molecular weight of 1562 daltonsNANOGEN INC·Filed 2001·Granted Jan 1, 2008·10 cites·9 claims
- 1174US6627608B2Biopolymer marker indicative of disease state having a molecular weight of 1206 daltonsSYN X PHARMA INC·Filed 2001·Granted Sep 30, 2003·15 cites·9 claims
- 1274US6593298B2Biopolymer marker indicative of disease state having a molecular weight of 1690 daltonsSYN X PHARMA INC·Filed 2001·Granted Jul 15, 2003·16 cites·9 claims
- 1373US8715648B2Method for treating obesity with anti-obesity formulations and omega 3 fatty acids for the reduction of body weight in cardiovascular disease patients (CVD) and diabeticsJACKOWSKI GEORGE·Filed 2012·Granted May 6, 2014·3 cites·37 claims
- 1472US6756476B2Biopolymer marker indicative of disease state having a molecular weight of 2021 daltonsSYN X PHARMA INC·Filed 2001·Granted Jun 29, 2004·14 cites·9 claims
- 1571US6599877B2Biopolymer marker indicative of disease state having a molecular weight of 1020 daltonsSYN X PHARMA INC·Filed 2001·Granted Jul 29, 2003·13 cites·9 claims
- 1669US6627607B2Biopolymer marker indicative of disease state having a molecular weight of 1845 daltonsSYN X PHARMA INC·Filed 2001·Granted Sep 30, 2003·12 cites·9 claims
- 1767US7294688B2Biopolymer marker indicative of disease state having a molecular weight of 1348 daltonsNANOGEN INC·Filed 2001·Granted Nov 13, 2007·5 cites·1 claims
- 1864US7125726B2Method and kit for diagnosing myocardial infarctionARTEMIS PROTEOMICS LTD·Filed 2005·Granted Oct 24, 2006·1 cites·5 claims
- 1957US6998243B2Biopolymer marker indicative of disease state having a molecular weight of 1793 daltonsSYN X PHARMA INC·Filed 2001·Granted Feb 14, 2006·1 cites·9 claims
- 2056US8951514B2Statin and omega 3 fatty acids for reduction of apolipoprotein-B levelsJACKOWSKI GEORGE·Filed 2012·Granted Feb 10, 2015·0 cites·15 claims
- 2156US8952000B2Cholesterol absorption inhibitor and omega 3 fatty acids for the reduction of cholesterol and for the prevention or reduction of cardiovascular, cardiac and vascular eventsJACKOWSKI GEORGE·Filed 2012·Granted Feb 10, 2015·0 cites·20 claims
- 2255US7049397B2Biopolymer marker indicative of disease state having a molecular weight of 1211 daltonsSYN X PHARMA INC·Filed 2001·Granted May 23, 2006·4 cites·9 claims
- 2354US2012302639A1Omega 3 formulations for treatment of risk factors for cardiovascular disease and protection against sudden deathJACKOWSKI GEORGE·Filed 2012·Application pending·0 cites
- 2454US2008096286A1Biopolymer marker indicative of disease state having a molecular weight of 1348 daltonsJACKOWSKI GEORGE·Filed 2007·Application pending·0 cites
- 2552US2006211048A1Biopolymer marker indicative of disease state having a molecular weight of 1211 daltonsJACKOWSKI GEORGE·Filed 2006·Application pending·0 cites
- 2651US8263351B2Diagnostic methods for congestive heart failureJACKOWSKI GEORGE·Filed 2011·Granted Sep 11, 2012·0 cites·7 claims
- 2751US7229638B2Biopolymer marker indicative of disease state having a molecular weight of 1525 DaltonsARTEMIS PROTEOMICS LTD·Filed 2005·Granted Jun 12, 2007·0 cites·8 claims
- 2850US2015272920A1Method for treating obesity with anti-obesity formulations and omega 3 fatty acids for the reduction of body weight in cardiovascular disease patients (cvd) and diabeticsJACKOWSKI GEORGE·Filed 2014·Application pending·0 cites
- 2950US2006024755A1Biopolymer marker indicative of disease state having a molecular weight of 1424 daltonsJACKOWSKI GEORGE·Filed 2005·Application pending·0 cites
- 3049US2009068676A1Diagnostic methods for congestive heart failureJACKOWSKI GEORGE·Filed 2007·Application pending·0 cites
- 3147US7087435B2Biopolymer marker indicative of disease state having a molecular weight of 2753 daltonsSYN X PHARMA INC·Filed 2001·Granted Aug 8, 2006·0 cites·8 claims
- 3246US9248138B2Process and composition for stabilization of vulnerable plaque utilizing a combination of a statin and omega 3 fatty acidsPIVOTAL THERAPEUTICS INC·Filed 2015·Granted Feb 2, 2016·0 cites·13 claims
- 3345US2004198950A1Biopolymer marker indicative of disease state having a molecular weight of 1518 daltonsFiled 2001·Application pending·0 cites
- 3445US2002160417A1Biopolymer marker indicative of disease state having a molecular weight of 1424 daltonsFiled 2001·Application pending·0 cites
- 3544US2006068505A1Biopolymer marker indicative of disease state having a molecular weight of 1077 daltonsJACKOWSKI GEORGE·Filed 2005·Application pending·0 cites
- 3644US2016128967A1Process and composition for stabilization of vulnerable plaque utilizing a combination of a statin and omega 3 fatty acidsPIVOTAL THERAPEUTICS INC·Filed 2015·Application pending·0 cites
- 3744US2005100964A1Diagnostic methods for congestive heart failureFiled 2003·Application pending·0 cites
- 3842US2015246012A1Omega 3 fatty acid for use as a prescription medical food and omega 3 fatty acid diagnostic assay for the dietary management of cardiovascular patients with cardiovascular disease (cvd) who are deficient in blood epa and dha levelsPIVOTAL THERAPEUTICS INC·Filed 2015·Application pending·0 cites
- 3942US2015119368A1Cholesterol absorption inhibitor and omega 3 fatty acids for the reduction of cholesterol and for the prevention or reduction of cardiovascular, cardiac and vascular eventsPIVOTAL THERAPEUTICS INC·Filed 2015·Application pending·0 cites
- 4042US2015119414A1Statin and omega 3 fatty acids for reduction of apolipoprotein-b levelsPIVOTAL THERAPEUTICS INC·Filed 2015·Application pending·0 cites
- 4142US2015224075A1Omega 3 formulations for treatment of risk factors for cardiovascular disease and protection against sudden deathPIVOTAL THERAPEUTICS INC·Filed 2015·Application pending·0 cites
- 4241US2002160423A1Biopolymer marker indicative of disease state having a molecular weight of 1536 daltonsFiled 2001·Application pending·0 cites
- 4341US2003040602A1Biopolymer marker indicative of disease state having a molecular weight of 1406 daltonsFiled 2001·Application pending·0 cites
- 4441US2002160434A1Biopolymer marker indicative of disease state having a molecular weight of 1777 daltonsFiled 2001·Application pending·0 cites
- 4541US2002160420A1Process for diagnosis of physiological conditions by characterization of proteomic materialsFiled 2001·Application pending·0 cites
- 4641US2002160418A1Biopolymer marker indicative of disease state having a molecular weight of 1949 daltonsFiled 2001·Application pending·0 cites
- 4741US2004224423A1Biopolymer marker indicative of disease state having a molecular weight of 2056 daltonsFiled 2001·Application pending·0 cites
- 4841US2002160532A1Biopolymer marker indicative of disease state having a molecular weight of 1998 daltonsFiled 2001·Application pending·0 cites
- 4938US6693080B2Biopolymer marker indicative of disease state having a molecular weight of 1521 daltonsSYN X PHARMA·Filed 2001·Granted Feb 17, 2004·0 cites·9 claims
- 5038US2002160533A1Biopolymer marker indicative of disease state having a molecular of weight of 1525 daltonsFiled 2001·Application pending·0 cites
Showing the top 50 of 52 patent records by PatentIndex Score.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →